WVP
NBIX icon

Worth Venture Partners’s Neurocrine Biosciences NBIX Stock Holding History

Worth Venture Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,393
Closed -$647K – 185
2023
Q1 		$647K Buy
+6,393
New +$665K 0.32% 73
2017
Q4 		– Sell
-11,469
Closed -$702K – 129
2017
Q3 		$702K Buy
+11,469
New +$605K 0.61% 34

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Worth Venture Partners's NBIX Position: Q2 2023 in Review

Worth Venture Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 6,393 shares — an estimated $647K sold.

Worth Venture Partners first reported a position in NBIX in Q3 2017 and held it in 2 quarters. The position peaked at $702K in Q3 2017. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • Worth Venture Partners reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
  • Worth Venture Partners sold 6,393 Neurocrine Biosciences shares in Q2 2023, an estimated $647K.
  • Worth Venture Partners first reported a position in Neurocrine Biosciences in Q3 2017 and held it in 2 quarters.
  • Worth Venture Partners's Neurocrine Biosciences position peaked at $702K in Q3 2017.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.